找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Lung Cancer; New Understandings a Anne C. Chiang,Roy S. Herbst Book 2021 Springer Nature Switzerland AG 2021 lung cancer.NSCLC.SCLC.lung ca

[复制链接]
楼主: 海市蜃楼
发表于 2025-3-23 10:46:35 | 显示全部楼层
发表于 2025-3-23 17:21:21 | 显示全部楼层
发表于 2025-3-23 20:34:31 | 显示全部楼层
发表于 2025-3-24 01:07:40 | 显示全部楼层
发表于 2025-3-24 03:05:53 | 显示全部楼层
Immune Therapy: What Can We Learn From Acquired Resistance?,sponse to these agents can be durable, but most patients will go on to develop resistance after initial tumor regression or prolonged disease stability. In patients with ‘acquired oligo-resistance,’ in whom progression is limited to two or less disease sites, local therapy may be an effective manage
发表于 2025-3-24 10:16:21 | 显示全部楼层
Management of Brain Metastases, brain metastases is increasing. Lung cancer is the most frequent origin of metastases to the brain, and this diagnosis is associated with significant morbidity as well as decreased quality of life and a worse prognosis. The treatment for brain metastases in NSCLC has historically been local therapy
发表于 2025-3-24 14:17:50 | 显示全部楼层
发表于 2025-3-24 16:14:21 | 显示全部楼层
发表于 2025-3-24 21:52:35 | 显示全部楼层
Small Cell Lung Cancer: Biology Advances,une checkpoint inhibitors have been approved for use in combination with etoposide plus a platinum agent as initial therapy for patients extensive stage SCLC; with the triplet regimen, the median overall survival is approximately 12 months. Over the past 4 years, several agents, including immune che
发表于 2025-3-24 23:51:13 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-26 06:26
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表